



Markets
/
Stocks
/
nasdaq-jnj
/

Johnson & Johnson

JNJ

View Detailed Chart

154.530USD

-0.400-0.26%

Close 04/25, 16:00（ET）Quotes delayed by 15 min

371.94BMarket Cap

26.44P/E TTM



Johnson & Johnson

154.530

-0.400-0.26%

Company

Intraday

30m

Today

-0.26%

5 Days

-1.87%

1 Month

-4.45%

6 Months

-3.95%

Year to Date

+6.85%

1 Year

+5.74%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 26 analysts

BUY

Current Rating

170.640

Target Price

10.39%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

160

Total

Median

Average

Company name

Ratings

Analysts

Johnson & Johnson

JNJ

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(6)

Neutral(4)

Buy(3)

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.868

Neutral

RSI(14)

46.584

Neutral

STOCH(KDJ)(9,3,3)

69.307

Neutral

ATR(14)

4.853

Low Volatility

CCI(14)

35.717

Neutral

Williams %R

26.692

Buy

TRIX(12,20)

-0.190

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

156.490

Sell

MA10

154.476

Buy

MA20

155.535

Sell

MA50

159.824

Sell

MA100

154.040

Buy

MA200

156.952

Sell

News

Over 60,000 claims filed! Can Johnson & Johnson escape? The judge's stance is unwavering!

Johnson & Johnson (JNJ) is trying to handle claims through a bankruptcy plan. But the judge rejected it. The stock price may continue to decline.

TradingKeyWed, Apr 2

US judge rejects J&J's $10 billion baby powder settlement

NEW YORK, March 31 (Reuters) - A U.S. bankruptcy judge on Monday rejected Johnson & Johnson's JNJ.N $10 billion proposal to end lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court.

ReutersTue, Apr 1

What Are Defensive Stocks? Should You Buy Them Now? Are Defense Stocks Defensive?

TradingKey - Defensive stocks are seen as "safe havens" during economic downturns because their products or services maintain stable demand regardless of economic cycles. Warren Buffett’s investment success is largely attributed to his preference for defensive blue-chip stocks.

TradingKeyFri, Mar 21

Worried About a Recession? 1 Healthcare Dividend Stock That Has Thrived In Every Market Crash

TradingKey - One of those sectors is healthcare and one of the biggest healthcare companies around is Johnson & Johnson (NYSE: JNJ), a company that also pays a decent dividend to shareholders.

TradingKeyFri, Mar 14

Johnson & Johnson Medtech Shockwave Medical Announces U.S. Launch Of Shockwave Javelin Peripheral IVL Catheter

March 4 (Reuters) - Johnson & Johnson JNJ.N:JOHNSON & JOHNSON MEDTECH: SHOCKWAVE MEDICAL ANNOUNCES U.S. LAUNCH OF SHOCKWAVE JAVELIN PERIPHERAL IVL CATHETER

ReutersTue, Mar 4

BUZZ-Johnson & Johnson falls after 2025 forecast hit from stronger dollar

Updates** Shares of Johnson & Johnson JNJ.N falls 3.56% to $142.81** For 2025, co sees operational sales between $90.9 billion and $91.7 billion and adj operational EPS to be in the range of $10.75 to $10.95** Co sees a 25-cent hit from a stronger dollar, which was above expectations, at least...

ReutersWed, Jan 22

Company

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.

Company codeJNJ

CompanyJohnson & Johnson

CEOMr. Joaquin Boix Duato

Websitehttps://www.jnj.com/